- Home
- TOPS vs KZR Comparison
TOPS vs KZR Comparison
Compare TOPS & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- KZR
- Stock Information
- Founded
- TOPS 2000
- KZR 2015
- Country
- TOPS Greece
- KZR United States
- Employees
- TOPS N/A
- KZR N/A
- Industry
- TOPS Marine Transportation
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- TOPS Consumer Discretionary
- KZR Health Care
- Exchange
- TOPS Nasdaq
- KZR Nasdaq
- Market Cap
- TOPS 27.2M
- KZR 29.7M
- IPO Year
- TOPS 2004
- KZR 2018
- Fundamental
- Price
- TOPS $5.46
- KZR $3.83
- Analyst Decision
- TOPS
- KZR Hold
- Analyst Count
- TOPS 0
- KZR 2
- Target Price
- TOPS N/A
- KZR $9.00
- AVG Volume (30 Days)
- TOPS 8.3K
- KZR 32.8K
- Earning Date
- TOPS 11-13-2025
- KZR 08-13-2025
- Dividend Yield
- TOPS N/A
- KZR N/A
- EPS Growth
- TOPS N/A
- KZR N/A
- EPS
- TOPS 1.09
- KZR N/A
- Revenue
- TOPS $86,127,000.00
- KZR N/A
- Revenue This Year
- TOPS $9.90
- KZR N/A
- Revenue Next Year
- TOPS N/A
- KZR N/A
- P/E Ratio
- TOPS $4.99
- KZR N/A
- Revenue Growth
- TOPS 3.83
- KZR N/A
- 52 Week Low
- TOPS $5.00
- KZR $3.62
- 52 Week High
- TOPS $11.47
- KZR $9.18
- Technical
- Relative Strength Index (RSI)
- TOPS 40.92
- KZR 38.14
- Support Level
- TOPS $5.40
- KZR $3.76
- Resistance Level
- TOPS $5.70
- KZR $4.10
- Average True Range (ATR)
- TOPS 0.23
- KZR 0.14
- MACD
- TOPS -0.01
- KZR 0.00
- Stochastic Oscillator
- TOPS 13.00
- KZR 14.44
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.